Med researchers in Austin have launched a clinical trial phase for a new drug they say could treat chronic pain, but a Texas judge is holding up the trial’s results until the state’s ethics commission reviews it.
The Texas Medical Association’s trial for the drug called VASAT, for Vascular Anterior Sclerosis and Arthritis Auto-Proteinase, started in May but has only received one week’s worth of results.
The trial, which aims to find the drug’s best-case and worst-case scenarios for a single patient, will be conducted at Texas Health Presbyterian Hospital in Houston, and the trial is expected to end sometime this fall.
The drug is designed to treat patients who have chronic pain due to multiple sclerosis, and it uses a gene therapy developed by the U.S. Army.
The trial’s primary goal is to find out if VASAPR, as it is commonly known, would reduce pain in people with MS.
A trial of that type can cost anywhere from $500,000 to $1 million, according to the study’s description.
The other key goal of the trial, according a news release from the Austin-based trial team, is to understand the clinical benefits of VASOPR in people who have other chronic conditions, like arthritis or fibromyalgia.
And it aims to see whether VASADO would be equally effective for people who don’t have MS, including those who have not had MS.
In a news conference Wednesday, VASAC’s co-lead investigator, Dr. Jason Tisch, said the study is designed specifically to look at patients with MS and chronic pain.
Tisch said the trial would focus on people with a variety of conditions, including MS, and that it would be open to people with any conditions.
“We are interested in the population we would be able to test,” he said.
“We don’t want to just look at people who are very sick.”
Tisch said that while the drug is being tested for MS, it would not be effective in people without MS.
“It would be very, very important to see if the drug works in people that are actually not MS patients,” he told reporters.
“That is what we are focusing on here.”
The study is part of a larger effort in the U